Next Article in Journal
Integrative Multi-Omics Reveals Microbiome and Genome Streamlining Underlie Ecological Divergence in Chinese and Xinjiang Cordyceps: A Preliminary Study
Previous Article in Journal
When Protection Turns Pathogenic: Dual Compartment Functions of Myeloid YB-1 in Renal IRI
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 27
Issue 12
10.3390/ijms27125240
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Int. J. Mol. Sci. 2026, 27(8), 3528.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Gad et al. Management of Childhood Obesity. Int. J. Mol. Sci. 2026, 27, 3528

by
Hoda Gad
1,
Hajar Dauleh
2,
Idris Mohammed
2,
Rayaz A. Malik
3,4 and
Khalid Hussain
2,*
1
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON M5T 3H7, Canada
2
Endocrinology Department, Sidra Medicine, Doha P.O. Box 26999, Qatar
3
Department of Medicine, Weill Cornell Medicine-Qatar, Doha P.O. Box 24144, Qatar
4
Institute of Cardiovascular Medicine, University of Manchester, Manchester M13 9PL, UK
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2026, 27(12), 5240; https://doi.org/10.3390/ijms27125240
Submission received: 12 May 2026 / Accepted: 25 May 2026 / Published: 10 June 2026
(This article belongs to the Section Molecular Biology)
Browse Figure
Versions Notes

Error in Figure

In the original publication [1], there was a mistake in Figure 1 as published. The titles for Alström syndrome and Bardet–Biedl syndrome in Figure 1, titled “Figure 1. Diagnostic approach and phenotypic spectrum of pediatric obesity.” were inadvertently altered.
The corrected Figure 1 appears below.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Gad, H.; Dauleh, H.; Mohammed, I.; Malik, R.A.; Hussain, K. Management of Childhood Obesity. Int. J. Mol. Sci. 2026, 27, 3528. [Google Scholar] [CrossRef] [PubMed]
Ijms 27 05240 g001
Figure 1. Diagnostic approach and phenotypic spectrum of pediatric obesity. Evaluation begins with screening for red flags (age of onset < 5 years and hyperphagia), which should prompt consideration of pathogenic causes other than polygenic obesity, including monogenic and syndromic forms. Secondary causes of obesity—such as medication-induced, endocrine, and hypothalamic disorders, as well as conditions associated with limited mobility—should also be excluded. The diagnostic pathway is organized into sequential steps: (1) initial evaluation for red flags, followed by (2a) assessment for secondary causes of obesity, (2b) evaluation for monogenic obesity, and (2c) evaluation for syndromic obesity. The lower panel summarizes key clinical characteristics, metabolic complications, and treatment approaches across the major categories of pediatric obesity. Polygenic obesity represents the most common form and is associated with environmental and behavioral risk factors. Monogenic obesity includes defects in the leptin–melanocortin pathway (LEP, LEPR, MC4R, POMC, and PCSK1), while syndromic obesity occurs in genetic disorders such as Prader–Willi syndrome (PWS), Alström syndrome, Bardet–Biedl syndrome (BBS), and Albright hereditary osteodystrophy. Abbreviations: LEP, leptin gene deficiency; LEPR, leptin receptor gene deficiency; MC4R, melanocortin 4 receptor deficiency; POMC, proopiomelanocortin deficiency; PCSK1, proprotein convertase subtilisin/kexin type 1 deficiency; PWS, Prader–Willi syndrome; BBS, Bardet–Biedl syndrome; T2DM, type 2 diabetes mellitus; AI, adrenal insufficiency; DI, diabetes insipidus; GHD, growth hormone deficiency; HH, hypogonadotropic hypogonadism; DD, developmental delay; PHPT, pseudohypoparathyroidism; AR, autosomal recessive; AD, autosomal dominant; UK, unknown inheritance; and AOM, anti-obesity medications.
Figure 1. Diagnostic approach and phenotypic spectrum of pediatric obesity. Evaluation begins with screening for red flags (age of onset < 5 years and hyperphagia), which should prompt consideration of pathogenic causes other than polygenic obesity, including monogenic and syndromic forms. Secondary causes of obesity—such as medication-induced, endocrine, and hypothalamic disorders, as well as conditions associated with limited mobility—should also be excluded. The diagnostic pathway is organized into sequential steps: (1) initial evaluation for red flags, followed by (2a) assessment for secondary causes of obesity, (2b) evaluation for monogenic obesity, and (2c) evaluation for syndromic obesity. The lower panel summarizes key clinical characteristics, metabolic complications, and treatment approaches across the major categories of pediatric obesity. Polygenic obesity represents the most common form and is associated with environmental and behavioral risk factors. Monogenic obesity includes defects in the leptin–melanocortin pathway (LEP, LEPR, MC4R, POMC, and PCSK1), while syndromic obesity occurs in genetic disorders such as Prader–Willi syndrome (PWS), Alström syndrome, Bardet–Biedl syndrome (BBS), and Albright hereditary osteodystrophy. Abbreviations: LEP, leptin gene deficiency; LEPR, leptin receptor gene deficiency; MC4R, melanocortin 4 receptor deficiency; POMC, proopiomelanocortin deficiency; PCSK1, proprotein convertase subtilisin/kexin type 1 deficiency; PWS, Prader–Willi syndrome; BBS, Bardet–Biedl syndrome; T2DM, type 2 diabetes mellitus; AI, adrenal insufficiency; DI, diabetes insipidus; GHD, growth hormone deficiency; HH, hypogonadotropic hypogonadism; DD, developmental delay; PHPT, pseudohypoparathyroidism; AR, autosomal recessive; AD, autosomal dominant; UK, unknown inheritance; and AOM, anti-obesity medications.
Ijms 27 05240 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Gad, H.; Dauleh, H.; Mohammed, I.; Malik, R.A.; Hussain, K. Correction: Gad et al. Management of Childhood Obesity. Int. J. Mol. Sci. 2026, 27, 3528. Int. J. Mol. Sci. 2026, 27, 5240. https://doi.org/10.3390/ijms27125240

AMA Style

Gad H, Dauleh H, Mohammed I, Malik RA, Hussain K. Correction: Gad et al. Management of Childhood Obesity. Int. J. Mol. Sci. 2026, 27, 3528. International Journal of Molecular Sciences. 2026; 27(12):5240. https://doi.org/10.3390/ijms27125240

Chicago/Turabian Style

Gad, Hoda, Hajar Dauleh, Idris Mohammed, Rayaz A. Malik, and Khalid Hussain. 2026. "Correction: Gad et al. Management of Childhood Obesity. Int. J. Mol. Sci. 2026, 27, 3528" International Journal of Molecular Sciences 27, no. 12: 5240. https://doi.org/10.3390/ijms27125240

APA Style

Gad, H., Dauleh, H., Mohammed, I., Malik, R. A., & Hussain, K. (2026). Correction: Gad et al. Management of Childhood Obesity. Int. J. Mol. Sci. 2026, 27, 3528. International Journal of Molecular Sciences, 27(12), 5240. https://doi.org/10.3390/ijms27125240

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop